NCT00349427View on ClinicalTrials.gov

A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

October 31, 2005

Conditions
Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
Interventions
DRUG

Rosiglitazone 4 mg

Trial Locations (10)

100029

GSK Investigational Site, Beijing

100034

GSK Investigational Site, Beijing

100730

GSK Investigational Site, Beijing

100853

GSK Investigational Site, Beijing

200001

GSK Investigational Site, Shanghai

200032

GSK Investigational Site, Shanghai

200233

GSK Investigational Site, Shanghai

210008

GSK Investigational Site, Nanjing

300052

GSK Investigational Site, Tianjin

710032

GSK Investigational Site, Xian

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY